Clinical trials: Multiple Sclerosis Relapse
Relapsing-remitting Multiple Sclerosis
Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis
Multiple sclerosis (MS) is the most common inflammatory demyelinating chronic disease of the central nervous system and the second leading cause of disability in young adults. Motor deficits also involve respiratory muscles.
- Trial name
- NCT02104492
- Testing
- a 12-week Respiratory Muscles Training Program (RMTP), Active Comparator
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Malaga
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Multiple Sclerosis
Imatinib for Multiple Sclerosis (MS) Relapses
To investigate if treatment with Imatinib results in a better outcome than standard care in form of Methylprednisolone(MP) after MS-associated relapses.
- Trial name
- NCT03674099
- Testing
- Imatinib Mesylate, Methylprednisolone
- Where
- 14 sites in Denmark, Germany and 2 more
- Volunteers
- 200 people
- Sponsor
- Tomas Olsson
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
Multiple sclerosis (MS) is a central nervous system inflammatory disease that causes a chronic and progressive physical handicap.
- Trial name
- SEPIA (NCT03471338)
- Testing
- Cognitive rehabilitation, Standard Psychological care
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Caen
Relapsing Remitting Multiple Sclerosis
Vitamin D Pilot Study in Patients With Multiple Sclerosis
Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.
- Trial name
- NCT01257958
- Testing
- 19 nor vitamin d
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Multiple Sclerosis, Relapsing-Remitting
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.
- Trial name
- NCT00276341
- Testing
- EGb 761® (Tanakan®)
- Where
- 30 sites in France
- Volunteers
- 47 people
- Sponsor
- Ipsen
Relapsing-remitting Multiple Sclerosis
Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS
Between 15-20% of MS patients decide not to initiate disease modifying therapies after being diagnosed with MS. For this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled…
- Trial name
- MIMS (NCT02010554)
- Testing
- Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Missouri, Kansas City
Multiple Sclerosis
Depression and Fatigue in MS Patients Treated With Betaferon.
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
- Trial name
- FADO (NCT01354665)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046)
- Where
- Poland
- Volunteers
- 567 people
- Sponsor
- Bayer
Multiple Sclerosis
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
The primary objective was to evaluate the long-term safety and tolerability of teriflunomide when added to treatment with interferon-β [IFN-β] or glatiramer Acetate [GA] in patients with multiple sclerosis [MS] with relapses.
- Trial name
- NCT00811395
- Testing
- Teriflunomide, Interferon-β [IFN-β], Glatiramer Acetate [GA]
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 182 people
- Sponsor
- Sanofi
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS).
- Trial name
- CHANGE-MS (NCT02782858)
- Testing
- GNbAC1
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 270 people
- Sponsor
- GeNeuro SA
Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting
- Trial name
- MS-GDI (NCT06516458)
- Testing
- Camera Based Kinematic Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Shirley Ryan AbilityLab
Optic Neuritis
Optic Neuritis Recovery After Oral or IV Corticosteroids
Patients aged 18-65 with acute demyelinating optic neuritis where treatment with high dose corticosteroids are already been chosen by the patient and the diagnosing physician will be contacted for screening and enrollment.
- Trial name
- NCT01524250
- Testing
- corticosteroids
- Where
- 2 sites in Canada
- Volunteers
- 51 people
- Sponsor
- London Health Sciences Centre
Multiple Sclerosis
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing…
- Trial name
- BRAVO (NCT00605215)
- Testing
- Laquinimod, Avonex®
- Where
- 170 sites in United States, Bulgaria and 17 more
- Volunteers
- 1,331 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthy Volunteers, Multiple Sclerosis
Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
In this first in human study the aim is to assess the safety, pharmacokinetics and pharmacodynamics of 2B3-201 in a randomized, first in human, double-blind, placebo- and active comparator- controlled 3-way crossover study in 18…
- Trial name
- NCT02048358
- Testing
- 2B3-201, Methylprednisolone hemisuccinate
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BBB-Therapeutics B.V.
Multiple Sclerosis, Relapsing-Remitting
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis
The aim of the study is to investigate reliability, validity, and responsiveness of the timed 360° turn test in patients with Multiple Sclerosis.
- Trial name
- NCT03718026
- Testing
- The timed 360° turn test
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Gazi University
Relapsing-Remitting Multiple Sclerosis
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of…
- Trial name
- NCT03284970
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis, Relapsing-Remitting
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.
- Trial name
- NCT01071694
- Testing
- Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
- Where
- South Korea
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant
Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently.
- Trial name
- CoQualSEP (NCT01392872)
- Testing
- Neuropsychological assessment
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Clermont-Ferrand
Relapsing Remitting Multiple Sclerosis
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
Randomized study designed to look at the difference in relapse rates between patients remaining on their current interferon medication and those switched to Copaxone®
- Trial name
- NCT00202995
- Testing
- Glatiramer Acetate, Betaseron, Rebif
- Volunteers
- 91 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
- Trial name
- NCT00035529
- Testing
- BMS 188667 (Abatacept)
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb